foxo4 dri senolytic 2023 2024 The disordered p53 transactivation domain is the target of and the compound FOXO4-DRI Senolytics: from pharmacological inhibitors to
Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment npj Aging Targeting the FOXO4 p53 axis by retro inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline Naunyn Schmiedeberg's Archives of Pharmacology Springer Nature Link FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway PMC Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data
Pay in 4 interest-free payments of $6.62 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15




